Skip to main content
Eupraxia Pharmaceuticals Inc. logo

Eupraxia Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · EPRX ISIN · CA29842P1053 TSX Manufacturing
Open in API
Filings indexed 226 across all filing types
Latest filing 2025-05-07 Regulatory Filings
Country CA Canada
Listing TSX EPRX

About Eupraxia Pharmaceuticals Inc.

https://eupraxiapharma.com/

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on developing targeted, extended-release therapies using its proprietary drug delivery platform, Diffusphere™. This technology is engineered to optimize local, controlled drug delivery directly to diseased tissues, aiming to maximize efficacy and minimize systemic side effects. Eupraxia addresses therapeutic areas with significant unmet medical needs, particularly in gastrointestinal and musculoskeletal diseases. The company's lead product candidate, EP-104GI, is currently in Phase 2 clinical trials for the treatment of Eosinophilic Esophagitis (EoE), a chronic inflammatory disease of the esophagus. The Diffusphere platform is designed to potentially offer long-term relief with fewer doses across various conditions, including inflammatory diseases, oncology, and pain.

Recent filings

Filing Released Lang Actions
52-109F2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a Form 52-109F2 Certification of Interim Filings by the CEO, which is a prescribed regulatory certification under Canadian NI 52-109 rather than the interim financial report or MD&A itself. It does not contain the full interim report, audit opinions, or MD&A content—it is a standalone management certification form. Therefore it does not match categories like IR (interim report), AR (audit), MDA (management discussion), or others, and falls into the fallback “Regulatory Filings” category.
2025-05-07 English
52-109F2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a Form 52-109F2 officer certification of interim filings (interim financial report and MD&A) under Canadian NI 52-109. It is not the interim report itself (IR), nor an audit report (AR), proxy statement (PSI), or other defined type. It is a regulatory certificate attesting to the quality of interim filings, so it falls into the fallback Regulatory Filings category.
2025-05-07 English
Interim MD&A - English.pdf
Management Reports Classification · 1% confidence The document is titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” for the three months ended March 31, 2025. It is an MD&A section relating to interim quarterly results, providing management’s narrative on financial conditions, results, and outlook. This corresponds exactly to the definition of a Management Report (MDA) rather than a full interim report or other announcement.
2025-05-07 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 1% confidence The document is a comprehensive set of unaudited interim consolidated financial statements for Eupraxia Pharmaceuticals Inc. for the three-month period ended March 31, 2025. It includes balance sheets, statements of operations, statements of changes in shareholders' equity, statements of cash flows, and detailed notes to the financial statements. This content constitutes a formal quarterly financial report, which fits the definition of an Interim/Quarterly Report (IR). Q1 2025
2025-05-07 English
News release - English.pdf
Earnings Release Classification · 1% confidence The document is a press release issued on May 6, 2025 providing Eupraxia Pharmaceuticals’ financial highlights and operational review for the first quarter of 2025 (net loss, cash runway, recent milestones, and upcoming webinar). It summarizes key quarterly financial results rather than presenting the full interim financial statements and MD&A in detail. This matches the definition of an Earnings Release (ER). Q1 2025
2025-05-07 English
Notice of the meeting and record date - English.pdf
Regulatory Filings Classification · 1% confidence The document is a TSX Trust Company notice confirming the record date and meeting date for the upcoming Annual General Meeting of EUPRAXIA PHARMACEUTICALS INC. It does not contain AGM materials or results, nor is it a proxy statement itself—rather it is a regulatory notice. There is no specific category for a “notice of record and meeting dates,” so it best fits the fallback category “Regulatory Filings (RNS).”
2025-03-21 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.